The effects of
3-aminopropylarsonate, an arsono analogue of
GABA, was tested on the development of electrically-kindled amygdala and on the expression of
generalized seizure activity in electrically and
NMDA fully amygdala-kindled rats. Intra-amygdaloid microinjection of
3-aminopropylarsonate (10 nmol in 0.5 microl injection vehicle) inhibited electrical epileptogenesis by keeping the seizure score at or below stage 1 on the Racine scale, and the afterdischarge duration (ADD) at or below 19.70 +/- 4.59 s. The effect was reversible after withdrawal of the
drug, since the animals developed a
generalized seizure activity when kindling stimuli continued in the absence of
drug. In fully electrically kindled animals with stage 5 amygdala-kindled
seizures, the
drug increased afterdischarge threshold (ADT) by 30-70%, without any effect on mean seizure score or ADD. The changes were reversible after 7 days. In fully
NMDA-kindled rats, intra-amygdala administration of
3-aminopropylarsonate (10 nmol/0.5 microl) 20 min before injection of
NMDA (4 nmol/0.5 microl) reduced the seizure score from 3.80 +/- 0.37(5) on the Racine scale to 0.83 +/- 0.40(6) (P < 0.01). The effect was partially reversible after washing with
phosphate buffer.
2-Amino-4-arsonobutyrate, the analogue of
glutamate, had no effect on seizure score following treatment with the same concentration of the
drug and the same route of injection. The inhibitory effect of
3-aminopropylarsonate on
NMDA kindled activity was dose-dependent, since higher doses of
NMDA reduced the effect of the
drug. The effect of
3-aminopropylarsonate was also selective to
NMDA receptors since it had no effect on
kainate-induced
seizures. With both models of kindling, no gross behavioural abnormalities were observed 3-6 months
after treatment with the
drug. These findings show the potent antiepileptogenic and anti-
convulsant activity of the arsonoanalogue of
GABA which appears to be non-toxic and therefore potentially useful as the basis for developing a new family of clinically useful
anticonvulsants for treating
epilepsy.